EG25095A - Phenyl-piperazines derivatives as serotonin reuptake inhibitors. - Google Patents
Phenyl-piperazines derivatives as serotonin reuptake inhibitors.Info
- Publication number
- EG25095A EG25095A EG2002101084A EG2002101084A EG25095A EG 25095 A EG25095 A EG 25095A EG 2002101084 A EG2002101084 A EG 2002101084A EG 2002101084 A EG2002101084 A EG 2002101084A EG 25095 A EG25095 A EG 25095A
- Authority
- EG
- Egypt
- Prior art keywords
- phenyl
- serotonin reuptake
- reuptake inhibitors
- piperazines
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101466 | 2001-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
EG25095A true EG25095A (en) | 2011-08-17 |
Family
ID=8160750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG2002101084A EG25095A (en) | 2001-10-04 | 2002-10-02 | Phenyl-piperazines derivatives as serotonin reuptake inhibitors. |
Country Status (39)
Country | Link |
---|---|
US (10) | US7144884B2 (fr) |
EP (2) | EP1436271B3 (fr) |
JP (3) | JP3896116B2 (fr) |
KR (3) | KR100842702B1 (fr) |
CN (1) | CN1319958C (fr) |
AR (2) | AR036659A1 (fr) |
AT (2) | ATE441631T1 (fr) |
AU (2) | AU2002333220C1 (fr) |
BE (1) | BE2014C036I2 (fr) |
BR (3) | BRPI0212733B8 (fr) |
CA (1) | CA2462110C (fr) |
CO (1) | CO5580746A2 (fr) |
CY (3) | CY1107924T1 (fr) |
DE (2) | DE60225162T3 (fr) |
DK (2) | DK1436271T6 (fr) |
EA (2) | EA007537B3 (fr) |
EG (1) | EG25095A (fr) |
ES (2) | ES2298425T7 (fr) |
FR (1) | FR14C0033I2 (fr) |
HK (1) | HK1072600A1 (fr) |
HR (1) | HRP20040220A2 (fr) |
HU (3) | HU230189B1 (fr) |
IL (1) | IL160655A0 (fr) |
IS (2) | IS2578B (fr) |
LT (1) | LTC1436271I2 (fr) |
LU (1) | LU92397I2 (fr) |
ME (1) | ME00039B (fr) |
MX (1) | MXPA04002959A (fr) |
MY (1) | MY140950A (fr) |
NL (1) | NL300652I1 (fr) |
NO (3) | NO326443B1 (fr) |
NZ (1) | NZ531556A (fr) |
PL (2) | PL210551B1 (fr) |
PT (2) | PT1436271E (fr) |
RS (2) | RS52865B (fr) |
SI (1) | SI1436271T1 (fr) |
UA (2) | UA81749C2 (fr) |
WO (1) | WO2003029232A1 (fr) |
ZA (1) | ZA200401583B (fr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
US7732463B2 (en) * | 2003-04-04 | 2010-06-08 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
AU2004226837A1 (en) * | 2003-04-04 | 2004-10-14 | H. Lundbeck A/S | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
UA81300C2 (en) * | 2003-04-04 | 2007-12-25 | Lundbeck & Co As H | Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture |
CN1767829A (zh) * | 2003-04-04 | 2006-05-03 | H.隆德贝克有限公司 | 作为5-羟色胺再摄取抑制剂的4-(2-苯氧基苯基)-哌啶或-1,2,3,6-四氢吡啶衍生物 |
EA010869B1 (ru) * | 2003-04-04 | 2008-12-30 | Х. Лундбекк А/С | Производные 4-(2-фенилсульфанилфенил)пиперидина в качестве ингибиторов повторного поглощения серотонина |
PL1701940T3 (pl) | 2003-12-23 | 2008-11-28 | H Lundbeck As | Pochodne 2-(1H-indolilosulfanylo)benzyloaminy jako SSRI |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
ATE435216T1 (de) * | 2005-02-10 | 2009-07-15 | Neurosearch As | Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
JP2007106746A (ja) * | 2005-09-13 | 2007-04-26 | Tosoh Corp | 新規アリールホモピペラジン類、またはその塩と製造方法 |
ATE508115T1 (de) * | 2006-06-16 | 2011-05-15 | Lundbeck & Co As H | Kristalline formen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin mit kombinierter serotonin- und norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen |
SI2044043T2 (sl) | 2006-06-16 | 2021-04-30 | H. Lundbeck A/S | 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje |
JP7179035B2 (ja) * | 2006-06-16 | 2022-11-28 | ハー・ルンドベック・アクチエゼルスカベット | 認識機能障害(cognitive impairment)を治療するための、組み合わされたセロトニン再取り込み、5-HT3および5-HT1A活性を有する化合物としての1-[2-(2,4-ジメチルフェニルスルファニル)-フェニル]ピペラジン |
CN101472891B (zh) * | 2006-06-16 | 2013-08-21 | H.隆德贝克有限公司 | 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式 |
CA2656057C (fr) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique |
TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
TWI432194B (zh) * | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | 4-〔2-(4-甲基苯硫基)苯基〕哌啶之新穎治療用途 |
TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | 4-〔2-(4-甲苯基硫基)-苯基〕哌啶之鹽類的液體調配物 |
WO2008151632A1 (fr) | 2007-06-15 | 2008-12-18 | H.Lundbeck A/S | 4-[2-(4-méthylphénylsulfanyl)phényl]pipéridine pour le traitement du syndrome du côlon irritable (ibs) |
TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
AU2014200364B2 (en) * | 2007-11-13 | 2015-09-17 | H. Lundbeck A/S | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity |
TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
TW200938194A (en) * | 2007-12-14 | 2009-09-16 | Lundbeck & Co As H | Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
WO2009081259A1 (fr) * | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Dérivés phénoxy-pyridylés |
UA98698C2 (en) * | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
DK2358675T3 (da) | 2008-11-14 | 2013-01-14 | Theravance Inc | 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser |
TW201033181A (en) * | 2009-02-17 | 2010-09-16 | Lundbeck & Co As H | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
NZ596431A (en) * | 2009-04-24 | 2012-12-21 | Lundbeck & Co As H | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
SI2470166T1 (sl) | 2009-08-24 | 2014-03-31 | H.Lundbeck A/S | Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina |
IN2012DN03846A (fr) * | 2009-10-30 | 2015-08-28 | Janssen Pharmaceutica Nv | |
EP2523945A1 (fr) * | 2010-01-11 | 2012-11-21 | Theravance, Inc. | Composés de type 1-(2-phénoxyméthylphényl)pipérazine comme inhibiteurs du recaptage de la sérotonine et de la norépinéphrine |
JP5769348B2 (ja) * | 2010-03-22 | 2015-08-26 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | 1−(2−フェノキシメチルヘテロアリール)ピペリジン化合物および1−(2−フェノキシメチルヘテロアリール)ピペラジン化合物 |
JP5787882B2 (ja) | 2010-04-30 | 2015-09-30 | 武田薬品工業株式会社 | 腸溶性錠剤 |
CA2797809A1 (fr) | 2010-04-30 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Comprime a delitage intestinal |
EP2407467A1 (fr) | 2010-07-14 | 2012-01-18 | Sandoz Ag | Composés cristallins de 1-[4-(2-azépan-1-yl-éthoxy)-benzyl]-2-(4-hydroxyphényl)-3-méthyl-1H-indol-5-ol et d'acide lactique |
TW201212918A (en) | 2010-08-23 | 2012-04-01 | Lundbeck & Co As H | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine |
ME03375B (fr) | 2011-06-20 | 2020-01-20 | H Lundbeck As | Indanes substitués 1-piperazino-3-phenyl deutérés pour le traitement de la schizophrénie |
KR102035877B1 (ko) | 2011-11-14 | 2019-10-23 | 알파시그마 에스.피.에이. | 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법 |
JP6018644B2 (ja) * | 2012-01-03 | 2016-11-02 | ハー・ルンドベック・アクチエゼルスカベット | 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]−ピペラジンの製造方法 |
US9499504B2 (en) | 2012-09-19 | 2016-11-22 | Sandoz Ag | Crystalline form of vortioxetine hydrobromide |
AP2015008498A0 (en) | 2012-12-13 | 2015-05-31 | Lundbeck & Co As H | Compositions comprising vortioxetine and donepezil |
KR102230628B1 (ko) * | 2013-02-22 | 2021-03-22 | 하. 룬드벡 아크티에셀스카브 | 보르티옥세틴 제조 방법 |
CN105283442B (zh) * | 2013-04-04 | 2018-04-13 | 斯洛文尼亚莱柯制药股份有限公司 | 用于合成1‑(2‑((2,4‑二甲基苯基)硫代)苯基)哌嗪的方法 |
CN104109135B (zh) * | 2013-04-22 | 2018-10-26 | 江苏豪森药业集团有限公司 | 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法 |
WO2015044963A1 (fr) | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | Vortioxétine amorphe et sels de ladite substance |
EP2878596A1 (fr) * | 2013-11-29 | 2015-06-03 | LEK Pharmaceuticals d.d. | Synthèse de vortioxetine via des intermédiaires de (2-(pipérazine-1-yl)phényl)lithium |
CN104710345B (zh) * | 2013-12-17 | 2017-09-05 | 江苏恩华药业股份有限公司 | 用于制备4‑(2‑(4‑甲基苯基硫基))苯基哌啶的化合物、其制备方法及应用 |
RU2679661C1 (ru) | 2013-12-20 | 2019-02-12 | Х. Лундбекк А/С | Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками |
EP2894154A1 (fr) | 2014-01-14 | 2015-07-15 | LEK Pharmaceuticals d.d. | Synthèse de vortioxetine via des intermédiaires de (2-(piperazine-1-yl)phényl)aniline |
CN103788019B (zh) * | 2014-01-22 | 2015-10-07 | 苏州明锐医药科技有限公司 | 沃替西汀的制备方法 |
US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
EP2930171A1 (fr) | 2014-04-07 | 2015-10-14 | LEK Pharmaceuticals d.d. | Synthèse de vortioxetine via intermédiaire de (2,4-diméthylphényl) (2-iodophényl)sulfane |
CN104059030B (zh) * | 2014-05-30 | 2016-05-04 | 镇江圣安医药有限公司 | [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途 |
FR3023320B1 (fr) * | 2014-07-03 | 2017-03-10 | Ifp Energies Now | Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial |
CZ2014471A3 (cs) * | 2014-07-08 | 2016-01-20 | Zentiva, K.S. | Způsob přípravy vortioxetinu |
US9687484B2 (en) | 2014-07-18 | 2017-06-27 | Dipharma Francis S.R.L. | Crystalline forms of an antidepressant compound |
CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
CN104292183B (zh) * | 2014-09-29 | 2016-01-06 | 杨献美 | 一种抗抑郁药物沃替西汀的制备方法 |
WO2016079751A2 (fr) | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | Procédé de préparation de vortioxétine et de polymorphes de cette substance |
EP3023417B1 (fr) | 2014-11-21 | 2017-06-28 | Dipharma Francis S.r.l. | Procédé pour la préparation d'un antidépresseur et ses intermédiaires |
CN104447622B (zh) * | 2014-11-28 | 2017-01-04 | 郑州大明药物科技有限公司 | 氢溴酸沃替西汀β晶型的制备方法 |
CN104586756A (zh) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | 一种含沃替西汀的口服溶液及其制备方法 |
CZ201531A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Polymerem stabilizované amorfní formy vortioxetinu |
CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
WO2016125190A2 (fr) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Nouvelles formes cristallines de vortioxétine, prémélanges, et procédés pour la préparation de ceux-ci |
WO2016125191A2 (fr) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Procédés de préparation de bromhydrate de vortioxétine |
US10227317B2 (en) | 2015-02-25 | 2019-03-12 | Lupin Limited | Process for the preparation of vortioxetine |
WO2016151328A1 (fr) | 2015-03-26 | 2016-09-29 | Cipla Limited | Procédé de fabrication d'inhibiteurs de la recapture de la sérotonine |
CN104829557B (zh) * | 2015-04-23 | 2017-06-27 | 山东百诺医药股份有限公司 | 一种新化合物1‑[2‑(2,4‑二甲基苯基硫基)苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用 |
JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
CA2992161A1 (fr) * | 2015-07-17 | 2017-01-26 | Institut Pasteur | Agent de stimulation du recepteur 1b de la 5-hydroxytryptamine destine a etre utilise comme promoteur de l'autorenouvellement et/ou de la differenciation des cellules satellites |
EP3337789A1 (fr) * | 2015-08-19 | 2018-06-27 | Amneal Pharmaceuticals Company GmbH | Procédé de préparation de bromhydrate de vortioxétine |
WO2017063771A1 (fr) * | 2015-10-14 | 2017-04-20 | Institut Pasteur | Agent de stimulation du récepteur 1b de la 5-hydroxytryptamine pour le traitement de l'infarctus du myocarde |
CN105348204B (zh) * | 2015-11-18 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途 |
CN105461635B (zh) * | 2015-11-18 | 2018-06-08 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
US11013830B2 (en) * | 2015-11-20 | 2021-05-25 | Institut Pasteur | 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential |
WO2017162536A1 (fr) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Promédicaments de vortioxétine |
US9820984B1 (en) | 2016-07-01 | 2017-11-21 | H. Lundbeck A/S | Dosing regimens for fast onset of antidepressant effect |
BR112019000706A8 (pt) | 2016-07-15 | 2022-12-06 | Pasteur Institut | Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo |
EA201990362A1 (ru) * | 2016-07-22 | 2019-07-31 | Цзянсу Нхвалокан Фармасьютикал Рисерч Энд Дивелопмент Ко., Лтд. | Аналог вортиоксетина и его применение и получение |
WO2018042168A1 (fr) | 2016-08-29 | 2018-03-08 | King, Lawrence | Composition pharmaceutique stable de bromhydrate de vortioxétine |
CN106349132B (zh) * | 2016-08-30 | 2018-02-02 | 重庆植恩药业有限公司 | 沃替西汀中间体杂质及其制备方法和用途 |
US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
CN108409728B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
CN108409729B (zh) * | 2017-02-09 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途 |
US10428033B2 (en) | 2017-02-15 | 2019-10-01 | Piramal Enterprises Limited | Process for the preparation of vortioxetine and salts thereof |
US11020390B2 (en) | 2017-02-17 | 2021-06-01 | Unichem Laboratories Ltd | Bioequivalent pharmaceutical composition of vortioxetine hydrobromide |
US10836730B2 (en) | 2017-02-23 | 2020-11-17 | Unichem Laboratories Ltd. | Process for preparation and purification of vortioxetine hydrobromide |
JP7121751B2 (ja) | 2017-04-25 | 2022-08-18 | ハー・ルンドベック・アクチエゼルスカベット | ボルチオキセチンHBr α型を製造するための方法 |
EP3412661A1 (fr) | 2017-06-08 | 2018-12-12 | Enantia, S.L. | Co-cristaux de bromhydrate vortioxetine et du résorcinol |
KR102026337B1 (ko) | 2017-07-07 | 2019-09-27 | 영진약품 주식회사 | 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법 |
CN107915685A (zh) * | 2017-12-11 | 2018-04-17 | 重庆植恩药业有限公司 | 一种氢溴酸沃替西汀中间体的制备方法 |
CN108017595A (zh) * | 2017-12-20 | 2018-05-11 | 安徽源久源科技有限公司 | 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法 |
WO2019242889A1 (fr) | 2018-06-20 | 2019-12-26 | Vio Ag Pharmaceuticals S.A. | Approche d'activation c-h organo-pseudocatalytique monotope pour la préparation de vortioxétine et d'intermédiaire de vortioxétine |
CN108727393B (zh) * | 2018-08-06 | 2019-10-29 | 广东东阳光药业有限公司 | 苯基二氮杂双环衍生物及其用途 |
CN108863986B (zh) * | 2018-08-06 | 2020-01-21 | 广东东阳光药业有限公司 | 二氟甲基取代的苯基哌嗪衍生物及其用途 |
WO2021198778A1 (fr) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-diméthylphénylsulfanyl)-phényl]pipérazine pour la prévention ou le traitement de l'émoussement émotionnel |
GB2622880A (en) | 2022-09-30 | 2024-04-03 | Alkaloid Ad Skopje | Palatable orodispersible formulation of vortioxetine |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS151753B1 (fr) | 1971-04-13 | 1973-11-19 | ||
CS151751B1 (fr) | 1971-04-13 | 1973-11-19 | ||
CS151755B1 (fr) | 1971-04-13 | 1973-11-19 | ||
CS151752B1 (fr) | 1971-04-13 | 1973-11-19 | ||
YU163075A (en) | 1975-07-21 | 1982-05-31 | Science Union & Cie | Process for preparing new phenoxy derivatives |
US4241071A (en) * | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
US4198419A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenylthiophenylpiperidines |
ES2004809A6 (es) * | 1987-07-29 | 1989-02-01 | Ferrer Int | Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas |
GB9126311D0 (en) | 1991-12-11 | 1992-02-12 | Wellcome Found | Substituted diphenylsulfides |
EP0755923B1 (fr) * | 1995-01-23 | 2005-05-04 | Daiichi Suntory Pharma Co., Ltd. | Ameliorant ou remede contre des symptomes provoques par des maladies ischemiques et composes phenylpiperidiniques utiles a cet effet |
CZ293595A3 (cs) | 1995-11-09 | 1999-12-15 | Farmak A. S. | Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích |
FR2757160B1 (fr) * | 1996-12-13 | 1999-03-12 | Sanofi Sa | 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
PT958280E (pt) * | 1997-10-31 | 2005-09-30 | Daiichi Suntory Pharma Co Ltd | Derivados de arilpiperidinopropanol e arilpiperazinopropanol e farmacos contendo os mesmos |
CN1721401A (zh) | 1999-04-02 | 2006-01-18 | 伊科斯公司 | 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途 |
AU6621600A (en) | 1999-08-04 | 2001-03-05 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
WO2001019678A1 (fr) * | 1999-09-14 | 2001-03-22 | Pharmacopeia, Inc. | Article comprenant une tete de distribution comportant des canaux multiples |
TR200201683T2 (tr) | 1999-12-30 | 2002-12-23 | H. Lundbeck A/S | İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları |
EP1246819A1 (fr) * | 1999-12-30 | 2002-10-09 | H. Lundbeck A/S | Procede de preparation de derives de benzene substitue |
US6813639B2 (en) | 2000-01-26 | 2004-11-02 | Viaclix, Inc. | Method for establishing channel-based internet access network |
DE10033548C2 (de) | 2000-07-11 | 2002-05-16 | Wolfgang Papenbrock | Verfahren zur Vorschau von Internetseiten |
US7186715B2 (en) * | 2001-01-08 | 2007-03-06 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
WO2002062766A2 (fr) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
ES2280595T3 (es) * | 2001-12-20 | 2007-09-16 | H. Lundbeck A/S | Derivados de ariloxifenilo y arilsulfanilfenilo. |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
US7732463B2 (en) * | 2003-04-04 | 2010-06-08 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
SI2044043T2 (sl) * | 2006-06-16 | 2021-04-30 | H. Lundbeck A/S | 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje |
-
2002
- 2002-02-10 UA UA2004032271A patent/UA81749C2/uk unknown
- 2002-09-30 AR ARP020103689A patent/AR036659A1/es active IP Right Grant
- 2002-10-02 RS RS20120158A patent/RS52865B/en unknown
- 2002-10-02 DK DK02800051.1T patent/DK1436271T6/da active
- 2002-10-02 PT PT02800051T patent/PT1436271E/pt unknown
- 2002-10-02 ME MEP-2008-65A patent/ME00039B/fr unknown
- 2002-10-02 ES ES02800051T patent/ES2298425T7/es active Active
- 2002-10-02 MX MXPA04002959A patent/MXPA04002959A/es active IP Right Grant
- 2002-10-02 AT AT06016609T patent/ATE441631T1/de active
- 2002-10-02 EG EG2002101084A patent/EG25095A/xx active
- 2002-10-02 PL PL392184A patent/PL210551B1/pl unknown
- 2002-10-02 DK DK06016609T patent/DK1749818T3/da active
- 2002-10-02 EP EP02800051.1A patent/EP1436271B3/fr not_active Expired - Lifetime
- 2002-10-02 BR BRPI0212733A patent/BRPI0212733B8/pt active IP Right Grant
- 2002-10-02 AU AU2002333220A patent/AU2002333220C1/en active Active
- 2002-10-02 ES ES06016609T patent/ES2328725T3/es not_active Expired - Lifetime
- 2002-10-02 BR BR122012023120A patent/BR122012023120B8/pt active IP Right Grant
- 2002-10-02 JP JP2003532482A patent/JP3896116B2/ja not_active Expired - Lifetime
- 2002-10-02 BR BR122012009534D patent/BR122012009534C8/pt not_active IP Right Cessation
- 2002-10-02 KR KR1020077022025A patent/KR100842702B1/ko active IP Right Grant
- 2002-10-02 AT AT02800051T patent/ATE386730T1/de active
- 2002-10-02 PT PT06016609T patent/PT1749818E/pt unknown
- 2002-10-02 EP EP06016609A patent/EP1749818B1/fr not_active Expired - Lifetime
- 2002-10-02 DE DE60225162.1T patent/DE60225162T3/de not_active Expired - Lifetime
- 2002-10-02 EA EA200400498A patent/EA007537B3/ru active Protection Beyond IP Right Term
- 2002-10-02 EA EA200601269A patent/EA011096B1/ru not_active IP Right Cessation
- 2002-10-02 WO PCT/DK2002/000659 patent/WO2003029232A1/fr active IP Right Grant
- 2002-10-02 CN CNB028190254A patent/CN1319958C/zh not_active Expired - Lifetime
- 2002-10-02 SI SI200230678T patent/SI1436271T1/sl unknown
- 2002-10-02 NZ NZ531556A patent/NZ531556A/en not_active IP Right Cessation
- 2002-10-02 PL PL368442A patent/PL209253B1/pl unknown
- 2002-10-02 HU HU1300028A patent/HU230189B1/hu unknown
- 2002-10-02 KR KR1020067022562A patent/KR100783346B1/ko active IP Right Grant
- 2002-10-02 KR KR1020047004897A patent/KR100770194B1/ko active Protection Beyond IP Right Term
- 2002-10-02 HU HU0402313A patent/HU228956B1/hu active Protection Beyond IP Right Term
- 2002-10-02 DE DE60233608T patent/DE60233608D1/de not_active Expired - Lifetime
- 2002-10-02 CA CA2462110A patent/CA2462110C/fr not_active Expired - Lifetime
- 2002-10-02 US US10/488,280 patent/US7144884B2/en active Active
- 2002-10-02 UA UAA200612495A patent/UA93857C2/uk unknown
- 2002-10-02 RS YU27704A patent/RS52326B/en unknown
- 2002-10-02 IL IL16065502A patent/IL160655A0/xx active Protection Beyond IP Right Term
- 2002-10-03 MY MYPI20023705A patent/MY140950A/en unknown
-
2004
- 2004-02-26 IS IS7164A patent/IS2578B/is unknown
- 2004-02-26 ZA ZA2004/01583A patent/ZA200401583B/en unknown
- 2004-03-05 HR HR20040220A patent/HRP20040220A2/hr not_active Application Discontinuation
- 2004-04-21 NO NO20041628A patent/NO326443B1/no not_active IP Right Cessation
- 2004-04-30 CO CO04039958A patent/CO5580746A2/es not_active Application Discontinuation
-
2005
- 2005-06-23 HK HK05105260A patent/HK1072600A1/xx not_active IP Right Cessation
- 2005-12-06 US US11/296,835 patent/US7138407B2/en not_active Expired - Lifetime
- 2005-12-06 US US11/296,836 patent/US7148238B2/en not_active Expired - Lifetime
-
2006
- 2006-09-14 AU AU2006215994A patent/AU2006215994B2/en not_active Ceased
- 2006-10-03 JP JP2006271762A patent/JP3955614B2/ja not_active Expired - Lifetime
- 2006-10-03 JP JP2006271758A patent/JP3955613B2/ja not_active Expired - Lifetime
- 2006-10-19 US US11/551,188 patent/US7683053B2/en not_active Expired - Fee Related
-
2008
- 2008-04-18 CY CY20081100436T patent/CY1107924T1/el unknown
- 2008-05-06 AR ARP080101915A patent/AR066460A2/es active IP Right Grant
- 2008-08-06 NO NO20083446A patent/NO332355B1/no not_active IP Right Cessation
-
2009
- 2009-03-10 IS IS8806A patent/IS2732B/is unknown
- 2009-10-14 CY CY20091101068T patent/CY1110064T1/el unknown
-
2010
- 2010-02-04 US US12/700,521 patent/US8110567B2/en not_active Expired - Fee Related
-
2012
- 2012-02-06 US US13/367,065 patent/US8476279B2/en not_active Expired - Lifetime
-
2013
- 2013-06-26 US US13/927,678 patent/US9090575B2/en not_active Expired - Fee Related
-
2014
- 2014-03-07 NL NL300652C patent/NL300652I1/nl unknown
- 2014-03-12 HU HUS1400012C patent/HUS1400012I1/hu unknown
- 2014-03-12 LU LU92397C patent/LU92397I2/fr unknown
- 2014-03-13 LT LTPA2014013C patent/LTC1436271I2/lt unknown
- 2014-04-16 FR FR14C0033C patent/FR14C0033I2/fr active Active
- 2014-05-13 NO NO2014011C patent/NO2014011I2/no not_active IP Right Cessation
- 2014-06-03 BE BE2014C036C patent/BE2014C036I2/nl unknown
- 2014-06-11 CY CY2014022C patent/CY2014022I2/el unknown
-
2015
- 2015-06-19 US US14/744,197 patent/US9708280B2/en not_active Expired - Lifetime
-
2017
- 2017-06-15 US US15/624,417 patent/US10844029B2/en not_active Expired - Lifetime
-
2020
- 2020-10-22 US US17/078,055 patent/US20210276966A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG25095A (en) | Phenyl-piperazines derivatives as serotonin reuptake inhibitors. | |
MXPA03008807A (es) | Derivados de ciclopropilindol como inhibidores selectivos de recaptacion de serotonina. | |
AU2002306491A1 (en) | Serotonin reuptake inhibitor formulations | |
MXPA02001919A (es) | Fenilpiperazinas novedosas. | |
AP2005003467A0 (en) | N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors. | |
ZA200407666B (en) | Pyridinoylpiperidines as 5-HTif agonists. | |
HK1090368A1 (en) | 2,3,6-trisubstituted-4-pyrimidone derivatives | |
AP2005003353A0 (en) | Diazepinoindole derivatives as kinase inhibitors. | |
AP2005003198A0 (en) | Spiroindolinepiperidine derivatives. | |
ZA200500170B (en) | Indole-3-sulphur derivatives. | |
MXPA03007093A (es) | Nueva composicion. | |
ZA200506744B (en) | PyrazoloÄ1,5-AÜpyrimidine derivatives | |
IL154343A0 (en) | Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors | |
MXPA03008140A (es) | Amidas de acido benzofuran-2-carboxilico sustituidas. | |
IL158141A0 (en) | Phenyl heterocyclyl ether derivatives as serotonin reuptake inhibitors | |
IL174187A0 (en) | Carbamoyl-type benzofuran derivatives | |
MXPA03001269A (es) | Nuevos derivados de aminociclohexano. | |
ZA200404807B (en) | Imidazoquinoline derivatives. | |
MXPA03008394A (es) | Derivados de biuretano. | |
GB0204596D0 (en) | Serotonin transport inhibitors |